German Life Sciences And Pharma Company Merck Kgaa Late On Friday Revealed That The European Commission Tepmetko Is The First And Only Oral Met Inhibitor To Be Approved In The European Economic Area For Treating Adult Patients With Advanced Nsclc Harboring Alterations Leading To Metex14 Skipping, Who Require Systemic Therapy Following Prior TreatmentApproval Is Based On Phase Ii Results From Vision, The Largest Interventional Study To Date Of Patients With Advanced Nsclc With Metex14 Skipping AlterationsTepmetko Demonstrated Consistent Responses Across Lines Of Therapy In The Vision Study Emd Serono, The Healthcare Business Of Merck Kgaa, Darmstadt, Germany In The Us And Canada, Today Announced That The European Commission (Ec) Has Approved Once-Daily Oral Tepmetko
